AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS

被引：5
|
作者：
El-Khoueiry, Anthony [1 ]
Bullock, Andrea [2 ]
Tsimberidou, Apostolia [3 ]
Mahadevan, Daruka [4 ]
Wilky, Breelyn [5 ]
Twardowski, Przemyslaw [6 ]
Bockorny, Bruno
Moser, Justin [7 ]
Feliu, Waldo Ortuzar [8 ]
Grossman, Joseph [8 ]
Rosenthal, Katherine [8 ]
O'Day, Steven [8 ]
Gordon, Michael [7 ]
机构：
[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
[6] St Johns Canc Inst, Santa Monica, CA USA
[7] HonorHlth Res Inst, Scottsdale, AZ USA
[8] Agenus Inc, Lexington, MA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.479
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
479
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [21] Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
    O'Malley, D.
    Neffa, M.
    Monk, B. J.
    Melkadze, T.
    Kryzhanivska, A.
    Bulat, I. V.
    Meniawy, T.
    Bondarenko, I.
    Feliu, W. I. Ortuzar
    Ancukiewicz, M.
    Lugowska, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S727 - S727
  • [22] A PHASE 1B/2 STUDY OF A NOVEL ANTI-CTLA-4 NEOBODYTM ADG116 MONOTHERAPY AND IN COMBINATION WITH TORIPALIMAB (TORI; ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS
    Park, John
    Hsien, Matthew
    Richardson, Gary
    Tolcher, Anthony
    Chon, Hong Jae
    Shin, Sang Joon
    Lim, Ho Yeong
    Hamid, Anis
    Li, Daneng
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Li, Ai
    Zhu, Lvyu
    Dai, Ruby
    Peng, Wei
    Lowe, Dana
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A785 - A785
  • [23] Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors
    Tanne, Antoine J.
    Vincent, Sylvia
    Duckless, Benjamin
    Paltrinieri, Elena
    Pabla, Simarjot
    Basinski, Andrew
    Pawaria, Sudesh
    Patel, Vidur
    Wilkens, Margaret
    Joshi, Bishnu
    Hancock, Matthew
    Levey, Daniel
    Horn, Thomas
    Joyce, Cailin
    Savitsky, David
    Gorman, Cori
    Buell, Jennifer
    Chand, Dhan
    CANCER RESEARCH, 2020, 80 (16)
  • [24] ENHANCED ANTI-TUMOR EFFECTS OF ANTI-CTLA-4 ANTIBODY AND ANTI-PD-1 ANTIBODY TO KIDNEY CANCER MODEL IN MICE
    Motoshima, Takanobu
    Komohara, Yoshihiro
    Hasita, Horlad
    Kawano, Yoshiaki
    Wada, Yoshihiro
    Takeya, Motohiro
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2014, 191 (04): : E372 - E373
  • [25] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [26] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [27] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [28] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [29] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas
    Kim, Kwang-Soo
    Habashy, Karl
    Gould, Andrew
    Zhao, Junfei
    Najem, Hinda
    Amidei, Christina
    Saganty, Ruth
    Arrieta, Victor A.
    Dmello, Crismita
    Chen, Li
    Zhang, Daniel Y.
    Castro, Brandyn
    Billingham, Leah
    Levey, Daniel
    Huber, Olivia
    Marques, Marilyn
    Savitsky, David A.
    Morin, Benjamin M.
    Muzzio, Miguel
    Canney, Michael
    Horbinski, Craig
    Zhang, Peng
    Miska, Jason
    Padney, Surya
    Zhang, Bin
    Rabadan, Raul
    Phillips, Joanna J.
    Butowski, Nicholas
    Heimberger, Amy B.
    Hu, Jian
    Stupp, Roger
    Chand, Dhan
    Lee-Chang, Catalina
    Sonabend, Adam M.
    NEURO-ONCOLOGY, 2024, 26 (11) : 2044 - 2060
  • [30] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
12345